Fredun Pharmaceuticals Limited has announced an Earnings Conference Call for the first quarter of FY27, scheduled for Thursday, 13th August, 2026 at 11:30 AM IST. The announcement was made pursuant to Regulation 30 read with sub para 15, Para A Part A Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The call will be hosted in association with Kirin Advisors and will feature the company's senior management.

Earnings Call Details

The Q1 FY27 Earnings Conference Call will be led by Mr. Fredun Medhora, Managing Director of Fredun Pharmaceuticals Limited. Participants are advised to dial in at least 10 minutes prior to the scheduled start time to ensure timely connectivity. The following table summarises the key joining details for the call:

Contact Information

For further information regarding the earnings call, participants may reach out to Kirin Advisors through the following channels:

• Phone: +91 22 4100 2455 / +91 93244 75886
• Email: research@kirinadvisors.com / info@kirinadvisors.com
• Website: www.kirinadvisors.com
• Address: 713-B Lodha Supremus II, Wagle Estate, Thane (W) 400 604

The intimation was signed by Fredun Medhora, Managing Director (DIN: 01745348) on 8th August, 2026.

Fredun Pharmaceuticals reported a robust start to FY27, with standalone net profit from continuing operations rising 95% year-on-year to ₹13.17 crore for the quarter ended June 30, 2026. The profit surge was driven by a 90% jump in total income to ₹228.25 crore, reflecting strong demand across its diversified portfolio of generics, cosmeceuticals, and nutraceuticals. This performance underscores the company’s operational efficiency and market positioning, offering shareholders confidence in its growth trajectory amid competitive industry dynamics.

The Board of Directors approved the unaudited financial results on August 5, 2026, in compliance with Regulation 47(1)(b) of SEBI Listing Regulations, 2015. The results were published in Active Times and Mumbai Lakshadeep newspapers on August 6, 2026, and filed with BSE Limited under Scrip Code 539730. Consolidated net profit also rose sharply to ₹13.13 crore from ₹6.77 crore in the year-ago quarter, while consolidated revenue mirrored standalone figures at ₹228.25 crore.

Financial Performance Highlights

The company's financial results for Q1FY27 demonstrate significant improvement across key metrics compared to the same period in the previous fiscal year. Revenue from operations, net of GST, stood at ₹227.75 million, up from ₹119.40 million in Q1FY26. Other operating income remained relatively flat at ₹0.49 million. Basic earnings per share (EPS) increased to ₹23.89 from ₹14.33, while diluted EPS stood at ₹22.25.

Operational Efficiency and Margins

The improvement in profitability was not just volume-driven but also reflected better margin retention. Cost of material consumed rose to ₹178.46 million from ₹90.33 million, aligning with the revenue growth trajectory. Other expenses were managed effectively, with employee benefits expenses decreasing slightly to ₹7.12 million from ₹7.63 million. Finance costs stood at ₹8.62 million compared to ₹6.53 million in the year-ago period, while depreciation and amortization expenses increased to ₹3.57 million from ₹1.42 million.

Capital Structure Update

On July 17, 2026, the company allotted 1.10 crore bonus equity shares in a 2:1 ratio to eligible shareholders. This issuance increased the issued and paid-up equity share capital from 55.13 lakh shares to 1.65 crore shares. The consistent public shareholding of 55.43% and stable promoter holding at 44.57% provide a steady ownership backdrop for this growth phase.

What the Numbers Show

The 90% revenue growth significantly outpaced the increase in material costs, indicating strong pricing power or a favorable product mix shift within the pharmaceutical portfolio. With no exceptional items or discontinued operations affecting the bottom line, the profit surge reflects core operational strength. Managing Director Fredun Medhora noted that long-term investments are translating into tangible outcomes, validating the company’s strategy to build a diversified healthcare entity with multiple growth engines.